Moretti C, Bagnato A, Solan N, Frajese G, Catt K J
Endocrinology and Reproduction Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda MD 20892.
Endocrinology. 1990 Nov;127(5):2117-26. doi: 10.1210/endo-127-5-2117.
GRF promotes follicular maturation and ovulation when administered with FSH in the treatment of infertility. Such actions could be mediated by stimulation of GH secretion and insulin-like growth factor I production, but the known actions of the structurally related hormone, vasoactive intestinal peptide (VIP), on granulosa cell function suggested that GRF may also act directly on the ovary to stimulate follicular development. Radioligand binding and activation studies, performed in granulosa cells from immature estrogen-treated rats, revealed a common receptor for VIP and rat (r) GRF in the ovary. Specific binding of [125I]VIP to granulosa cells was saturable and dependent on time and temperature. The relative potencies of VIP-related peptides for inhibition of radioligand binding were: VIP greater than rGRF greater than peptide histidine isoleucinamide greater than [His1,Nle27] human GRF(1-32)NH2 greater than secretin. In binding studies with the potent GRF agonist, [125I] [His1,Nle27]GRF(1-32)NH2, relative potencies were: rGRF(1-43)OH greater than [His1,Nle27]human GRF(1-32)NH2 greater than VIP greater than peptide histidine isoleucinamide greater than secretin. Glucagon and gastric inhibitory peptide, other peptides of the glucagon superfamily, and unrelated peptides including CRF and beta-endorphin, did not inhibit binding of either radioligand to ovarian receptors. In cultured granulosa cells, rGRF and VIP stimulated cAMP formation, consistent with coupling of their receptors to the adenylate cyclase system, and potentiated FSH-induced cAMP production. Both peptides also amplified FSH-induced progesterone biosynthesis, aromatase activity, and LH receptor formation. These observations demonstrate that rGRF is a potent cAMP-mediated agonist in the rat ovary and acts on a common VIP/GRF receptor in maturing granulosa cells. It is likely that the potentiating effect of administered GRF on gonadotropin-stimulated follicular development in vivo is in part mediated by direct actions of the peptide on the VIP/GRF receptor. Also, since GRF is present in the gonads, it is possible that the locally-produced peptide promotes follicular maturation by paracrine modulation of the stimulatory action of FSH on granulosa cell function.
在治疗不孕症时,生长激素释放因子(GRF)与促卵泡激素(FSH)联合使用可促进卵泡成熟和排卵。这些作用可能是通过刺激生长激素(GH)分泌和胰岛素样生长因子I产生来介导的,但结构相关激素血管活性肠肽(VIP)对颗粒细胞功能的已知作用表明,GRF也可能直接作用于卵巢以刺激卵泡发育。在未成熟雌激素处理大鼠的颗粒细胞中进行的放射性配体结合和激活研究显示,卵巢中存在VIP和大鼠(r)GRF的共同受体。[125I]VIP与颗粒细胞的特异性结合是可饱和的,且依赖于时间和温度。VIP相关肽抑制放射性配体结合的相对效力为:VIP大于rGRF大于肽组氨酸异亮氨酸酰胺大于[His1,Nle27]人GRF(1-32)NH2大于促胰液素。在用强效GRF激动剂[125I][His1,Nle27]GRF(1-32)NH2进行的结合研究中,相对效力为:rGRF(1-43)OH大于[His1,Nle27]人GRF(1-32)NH2大于VIP大于肽组氨酸异亮氨酸酰胺大于促胰液素。胰高血糖素和胃抑制肽,胰高血糖素超家族的其他肽,以及包括促肾上腺皮质激素释放因子(CRF)和β-内啡肽在内的无关肽,均不抑制任何一种放射性配体与卵巢受体的结合。在培养的颗粒细胞中,rGRF和VIP刺激环磷酸腺苷(cAMP)形成,这与其受体与腺苷酸环化酶系统偶联一致,并增强了FSH诱导的cAMP产生。这两种肽还增强了FSH诱导的孕酮生物合成、芳香化酶活性和促黄体生成素(LH)受体形成。这些观察结果表明,rGRF在大鼠卵巢中是一种强效的cAMP介导激动剂,并作用于成熟颗粒细胞中的共同VIP/GRF受体。给予的GRF对体内促性腺激素刺激的卵泡发育的增强作用可能部分是由该肽对VIP/GRF受体的直接作用介导的。此外,由于GRF存在于性腺中,局部产生的该肽有可能通过旁分泌调节FSH对颗粒细胞功能的刺激作用来促进卵泡成熟。